Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
2.
Int J Radiat Oncol Biol Phys ; 10(7): 971-6, 1984 Jul.
Article in English | MEDLINE | ID: mdl-6746358

ABSTRACT

Patients with bulky prostate cancer have usually been treated by palliative measures because the likelihood of tumor control with definitive irradiation has been low and the development of distant metastases high. The addition of estrogen to irradiation has not been shown to be of value. However, we believe the method of estrogen administration may have been the cause for the apparent lack of benefit. Estrogen had been started either concurrent with irradiation or had been used for palliation and was given for long and unscheduled time periods prior to irradiation. We have used estrogen for two months prior to and concurrent with irradiation. We postulated that in those patients with estrogen responsive cancer, the reduced tumor burden prior to irradiation could enhance tumor control and survival. Between 1975 and 1980, 25 patients with bulky prostate cancer received sequential estrogen and irradiation, 12 patients irradiation alone and six patients irradiation after having become refractory to long-term estrogen use. One patient was lost to follow-up. Eighteen of 25 (72%) treated by sequential estrogen and irradiation, 14/17 (82%) with estrogen responsive cancer and 4/8 (50%) with estrogen resistant cancer had a complete tumor response. Six of 11 (55%) patients treated by irradiation alone and 2/6 (33%) treated by irradiation for estrogen refractory cancer had a complete tumor response. Disease-free survival was observed in 13/25 (52%) treated by sequential estrogen and irradiation, and 8/17 patients (47%) with irradiation. It is also possible the improved survival in the estrogen responsive group was a direct result of improved local control. Persistent local disease can act as a source for distant metastases. Distant metastases was observed in 15% of patients when the primary tumor was controlled and 30% when there was persistent or recurrent local disease. Also, progressive local disease can be an important cause of death. This was most evident in our patients with estrogen refractory cancer. Almost all patients in this group had progressive local disease that caused serious urinary bleeding and urinary infection that were considered the major cause of death. Our results suggest bulky prostate cancer should be aggressively treated when first diagnosed. The value of adjunct estrogen is unproven. Our results with the use of estrogen prior to and concurrent with irradiation is encouraging. Estrogen may shrink the cancer and allow for a more favorable geometry for external irradiation. Tumor control and survival may be thereby improved.(ABSTRACT TRUNCATED AT 400 WORDS)


Subject(s)
Estrogens/therapeutic use , Prostatic Neoplasms/radiotherapy , Aged , Combined Modality Therapy , Estrogens/administration & dosage , Humans , Male , Middle Aged , Prostatic Neoplasms/drug therapy
3.
Dis Colon Rectum ; 22(3): 172-4, 1979 Apr.
Article in English | MEDLINE | ID: mdl-446250

ABSTRACT

We report a case of reno-colic fistula with abscess formation, which was treated by staged surgical procedures. One must be wary of automatically implicating the colon as the primary source of the problem when the colon and adjacent organs are involved in an inflammatory process. In cases involving the superior segments of the colon, the kidney or pancreas may be the source of the fistula.


Subject(s)
Colonic Diseases/complications , Intestinal Fistula/complications , Kidney Diseases/complications , Nephrosis/complications , Urinary Fistula/complications , Colonic Diseases/surgery , Female , Humans , Intestinal Fistula/surgery , Kidney Diseases/surgery , Middle Aged , Urinary Fistula/surgery
SELECTION OF CITATIONS
SEARCH DETAIL
...